CLINICAL FEATURES OF CHRONIC KIDNEY DISEASE STAGE 5 IN PATIENTS TREATED WITH PROGRAMMED HEMODIALYSIS
DOI:
https://doi.org/10.11603/1811-2471.2025.v.i2.15124Keywords:
CKD 5, hemodialysis, anemia, type 2 diabetes mellitus, glomerulonephritisAbstract
Summary. Chronic kidney disease (CKD) is a complex problem of modern society that goes far beyond medical aspects. It causes a significant reduction in the duration and deterioration of the quality of life of patients, and also creates a burden on the economy and social sphere. The consequences of CKD cause the appearance of concomitant complications, such as insomnia, skin itching and anemia. They, in turn, lead to depression and anxiety, which is a significant problem that requires additional attention.
The aim – to analyze the clinical manifestations of CKD, prolonged by programmed hemodialysis, depending on the main diagnosis: type 2 diabetes mellitus, arterial hypertension, polycystic kidney disease and chronic glomerulonephritis.
Material and Methods. The study included 129 patients who were treated at the Center for Nephrology and Dialysis of the 1st TMO of Lviv. Depending on the underlying disease, patients were divided into the following groups: group 1 – 29 patients with chronic glomerulonephritis, group 2 – 18 patients with polycystic kidney disease, group 3 – 46 patients with arterial hypertension and group 4 – 36 patients with type 2 diabetes mellitus. Among the examined, there were 73 men and 56 women, the average age was 57.2±12.8 years.
Results. Anemia was the most common complication of programmed dialysis in all groups of patients without a significant difference in the frequency of detection (p>0.05). Resistant hypertension was most often detected in patients with chronic glomerulonephritis, while in the group with polycystic kidney disease it was not recorded at all (p<0.05). Disorders of calcium-phosphorus metabolism and insomnia were found in all groups with a statistically insignificant difference (p>0.05).
Conclusions. The conducted study confirmed the significant impact of CKD on the quality of life of patients on hemodialysis. The high prevalence of complications such as resistant arterial hypertension, disorders of calcium-phosphorus metabolism, insomnia, skin itching and anemia indicates the need for a comprehensive approach to the treatment of these patients.
References
Kolesnyk M, Kozliuk N, Razvazhaeva O. National Registry of Patients with Chronic Kidney Disease and Patients with Acute Kidney Injury 20 years: acquisitions and perspectives. Ukrainian Journal of Nephrology and Dialysis. 2022; 4(76):3-9. DOI: https://doi.org/10.31450/ukrjnd.4(76).2022.01
Okpechi IG, Bello AK, Levin A, Johnson DW. Update on variability in organization and structures of kidney care across world regions. Kidney Int Suppl. 2024;13(1):6-11. DOI: https://doi.org/10.1016/j.kisu.2023.12.002
Smyth C. The Pittsburgh sleep quality index (PSQI). J Gerontol Nurs. 1999;25(12):10-10. DOI: https://doi.org/10.3928/0098-9134-19991201-10
Croatian Society of Nephrology, Dialysis and Transplantation, Croatian Medical Association. Smjernice za lijecenje anemije u bolesnika s kronicnim zatajenjem bubrega [Clinical practice guideline for anemia management in chronic kidney disease]. Acta Med Croatica. 2009;63 Suppl 1:78–88.
Romagnani P, Kitching AR, Leung N, Anders HJ. The five types of glomerulonephritis classified by pathogenesis, activity and chronicity (GN-AC). Nephrol Dial Transplant. 2023;38(Suppl 2):ii3–ii10. DOI:10.1093/ndt/gfad067 DOI: https://doi.org/10.1093/ndt/gfad067
Calhoun DA, Jones D, Textor S, et al. Rezystentna arterial'na hipertenziya: postanovka diahnozu, otsinka ta likuvannya. Naukove tverdzhennya Profesiynoyi osvitn'oyi komisiyi z doslidzhen' pidvyshchenoho arterial'noho tysku Amerykans'koyi asotsiatsiyi sertsya (Osnovni polozhennya – referat) [Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee on High Blood Pressure (Core Statements –Abstract)]. Novyny medytsyny ta farmatsii. 2018;18(625). Available from: http://www.mif-ua.com/archive/article/ 6259. Ukrainian.
Flythe JE, Watnick S. Dialysis for Chronic Kidney Failure: A Review. JAMA. 2024;332(18):1559-73. DOI:10.1001/jama.2024.16338 DOI: https://doi.org/10.1001/jama.2024.16338
Hu L, Napoletano A, Provenzano M, et al. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic. Int J Mol Sci. 2022;23(20):12223. DOI:10.3390/ijms232012223 DOI: https://doi.org/10.3390/ijms232012223
Rastogi A, et al. Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm. J Ren Nutr. 2021;31(1):21-34. DOI: 10.1053/j.jrn.2020.02.003 DOI: https://doi.org/10.1053/j.jrn.2020.02.003
Combe C, Mann J, Goldsmith D, et al. Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. BMC Nephrol. 2019;20(1):81. DOI:10.1186/s12882-019-1251-z DOI: https://doi.org/10.1186/s12882-019-1251-z
Gesualdo L, Combe C, Covic A, et al. Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). Int Urol Nephrol. 2015;47(5):837-45. DOI:10.1007/s11255-015-0970-8 DOI: https://doi.org/10.1007/s11255-015-0970-8
Simonsen E, et al. Treatment of Uremic Pruritus: A Systematic Review. Am J Kidney Dis. 2017;70(5):638-55. DOI:10.1053/j.ajkd.2017.05.018 DOI: https://doi.org/10.1053/j.ajkd.2017.05.018
Schricker S, Kimmel M. Unravelling the pathophysiology of chronic kidney disease-associated pruritus. Clin Kidney J. 2021;14(Suppl 3):i23–i31. DOI:10.1093/ckj/sfab200 DOI: https://doi.org/10.1093/ckj/sfab200
Rehman IU, Chohan TA, Bukhsh A, Khan TM. Impact of Pruritus on Sleep Quality of Hemodialysis Patients: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2019;55(10):699. DOI:10.3390/medicina55100699 DOI: https://doi.org/10.3390/medicina55100699
Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87(4):685-91. DOI:10.1038/ki.2013.454 DOI: https://doi.org/10.1038/ki.2013.454
Hong JSW, Atkinson LZ, Al-Juffali N, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Mol Psychiatry. 2022;27(3):1339-49. DOI:10.1038/s41380-021-01386-6 DOI: https://doi.org/10.1038/s41380-021-01386-6